4 unknown, 2 terminated, 1 completed, 1 recruiting. 3 Phase 1, 3 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Not applicable | 2 | Unknown 2 |
Follow Prostatic Disease: new trials by email Literature Review of Prostatic Disease trials Research Report on Prostatic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | Phase 1 / Phase 2 | Recruiting | Celcuity Inc | 54 | 2024-01-01 | 2026-04-13 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC 177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 93 | 2022-04-29 | 2023-12-15 |
| 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical [68Ga]Ga-HTK03149 PET/CT - Prostate Cancer, Prostatic Neoplasm | Not applicable | Unknown | British Columbia Cancer Agency | 10 | 2021-08-30 | 2021-12-03 |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy 18F-PSMA - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Terminated | Alessandro D'Agnolo | 62 | 2021-04-06 | 2026-07-22 |
| Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA SoracteLite(TM) TPLA for BPH - Male Urogenital Diseases, Genital Diseases, Male | Phase 1 | Unknown | Urological Research Network, LLC | 20 | 2020-11-20 | 2023-01-26 |
| Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed [68Ga]Ga-PSMA-11 PET/CT - Prostate Cancer, Prostatic Neoplasm | Not applicable | Unknown | Azienda Ospedaliero-Universitaria di Modena | 100 | 2020-09-20 | 2020-09-17 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) P-PSMA-101 CAR-T cells, Rimiducid - Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type | Phase 1 | Terminated | Poseida Therapeutics, Inc. | 40 | 2020-02-28 | 2025-02-17 |
| Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment Lymphoma, Digestive System Diseases | Completed | Institut Bergonié | 364 | 2002-09-01 | 2022-02-04 |
Prostatic Diseases (8) · Neoplasms (6) · Prostatic Neoplasms (6) · Urogenital Neoplasms (5) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Neoplasms by Site (3) · Disease Attributes (2) · Male Urogenital Diseases (2) · Prostatic Neoplasms, Castration-Resistant (2) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Mucoepidermoid (1) · Digestive System Diseases (1) · Lung Diseases (1)
Genital Diseases (8) · Urogenital Diseases (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (6) · Genital Diseases, Male (5) · Genital Neoplasms, Male (3) · Neoplasms by Site (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urologic Diseases (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma (1) · Endocrine System Diseases (1)
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Ipilimumab (1) · Nivolumab (1) · Pluvicto (1) · darolutamide (1) · gedatolisib (1)
Alessandro D'Agnolo (1) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Azienda Ospedaliero-Universitaria di Modena (1) · British Columbia Cancer Agency (1) · Celcuity Inc (1) · Institut Bergonié (1) · Poseida Therapeutics, Inc. (1) · Urological Research Network, LLC (1)
United States (4) · France (2) · Australia (1) · Canada (1) · Italy (1) · Spain (1) · United Kingdom (1)
Alessandro D'Agnolo, MD (1) · Fernando Bianco, MD (1) · Nadene Zack, MS (1) · Rajesh Belani, M.D. (1) · Shahneen Sandhu, MBBS, FRACP (1)
PMID 22508806, PMID 24062399, PMID 37682613, PMID 40767026, PMID 41748290
2019 (1)